0 CHECKOUT

Growth Hormone Deficiency - Pipeline Review, H2 2015

  • ID: 3495977
  • October 2015
  • 111 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aeterna Zentaris Inc.
  • Biogenomics Limited
  • Carlina Technologies SAS
  • Flamel Technologies S.A.
  • LG Life Sciences Limited
  • Pfenex Inc.
  • MORE

Growth Hormone Deficiency - Pipeline Review, H2 2015

Summary

The report ‘Growth Hormone Deficiency - Pipeline Review, H2 2015’, provides an overview of the Growth Hormone Deficiency’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aeterna Zentaris Inc.
  • Biogenomics Limited
  • Carlina Technologies SAS
  • Flamel Technologies S.A.
  • LG Life Sciences Limited
  • Pfenex Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Growth Hormone Deficiency Overview

Therapeutics Development

Pipeline Products for Growth Hormone Deficiency - Overview

Pipeline Products for Growth Hormone Deficiency - Comparative Analysis

Growth Hormone Deficiency - Therapeutics under Development by Companies

Growth Hormone Deficiency - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Growth Hormone Deficiency - Products under Development by Companies

Growth Hormone Deficiency - Companies Involved in Therapeutics Development

Aeterna Zentaris Inc.

Aileron Therapeutics, Inc.

Ascendis Pharma A/S

Biogenomics Limited

Bolder Biotechnology, Inc.

Braasch Biotech LLC

Carlina Technologies SAS

Critical Pharmaceuticals Limited

Delpor, Inc.

Flamel Technologies S.A.

Genexine, Inc.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Inbiopro Solutions Pvt. Ltd.

JCR Pharmaceuticals Co., Ltd.

LG Life Sciences Limited

OPKO Health, Inc.

Pfenex Inc.

Prometheon Pharma, LLC

Teva Pharmaceutical Industries Limited

Versartis, Inc.

XL-protein GmbH

Growth Hormone Deficiency - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ACP-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

albutropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALRN-5281 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BBT-031 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CP-016 SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CP-024 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GXH-9 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HL-032 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HM-10560A - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IBPB-003HH - Drug Profile

Product Description

Mechanism of Action

R&D Progress

macimorelin acetate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MOD-4023 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pegylated Somatropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatotropin SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatotropin SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin biobetter - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin biobetter - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin pegol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somatropin SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

somavaratan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Growth Hormone Deficiencies - Drug Profile

Product Description

Mechanism of Action

R&D Progress

XL-020 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Growth Hormone Deficiency - Recent Pipeline Updates

Growth Hormone Deficiency - Dormant Projects

Growth Hormone Deficiency - Discontinued Products

Growth Hormone Deficiency - Product Development Milestones

Featured News & Press Releases

Oct 01, 2015: Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting

Sep 18, 2015: Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children

Sep 10, 2015: Versartis Initiates Phase 2 Trial of Monthly Somavaratan in Adults With Growth Hormone Deficiency

Sep 08, 2015: Versartis Announces Agenda and Event Details for Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency

Aug 05, 2015: Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology

Aug 04, 2015: Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology

Jul 30, 2015: Ascendis Pharma Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency

Jul 10, 2015: Opko Announces Completion Of Enrollment In Phase 3 Trial Of Hgh-Ctp In Growth Hormone Deficient Adults

Jul 06, 2015: Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Growth Hormone Deficiency, H2 2015

Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Growth Hormone Deficiency - Pipeline by Aeterna Zentaris Inc., H2 2015

Growth Hormone Deficiency - Pipeline by Aileron Therapeutics, Inc., H2 2015

Growth Hormone Deficiency - Pipeline by Ascendis Pharma A/S, H2 2015

Growth Hormone Deficiency - Pipeline by Biogenomics Limited, H2 2015

Growth Hormone Deficiency - Pipeline by Bolder Biotechnology, Inc., H2 2015

Growth Hormone Deficiency - Pipeline by Braasch Biotech LLC, H2 2015

Growth Hormone Deficiency - Pipeline by Carlina Technologies SAS, H2 2015

Growth Hormone Deficiency - Pipeline by Critical Pharmaceuticals Limited, H2 2015

Growth Hormone Deficiency - Pipeline by Delpor, Inc., H2 2015

Growth Hormone Deficiency - Pipeline by Flamel Technologies S.A., H2 2015

Growth Hormone Deficiency - Pipeline by Genexine, Inc., H2 2015

Growth Hormone Deficiency - Pipeline by HanAll Biopharma Co., Ltd., H2 2015

Growth Hormone Deficiency - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015

Growth Hormone Deficiency - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015

Growth Hormone Deficiency - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015

Growth Hormone Deficiency - Pipeline by LG Life Sciences Limited, H2 2015

Growth Hormone Deficiency - Pipeline by OPKO Health, Inc., H2 2015

Growth Hormone Deficiency - Pipeline by Pfenex Inc., H2 2015

Growth Hormone Deficiency - Pipeline by Prometheon Pharma, LLC, H2 2015

Growth Hormone Deficiency - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015

Growth Hormone Deficiency - Pipeline by Versartis, Inc., H2 2015

Growth Hormone Deficiency - Pipeline by XL-protein GmbH, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Growth Hormone Deficiency Therapeutics - Recent Pipeline Updates, H2 2015

Growth Hormone Deficiency - Dormant Projects, H2 2015

Growth Hormone Deficiency - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Growth Hormone Deficiency, H2 2015

Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Aeterna Zentaris Inc.
Aileron Therapeutics, Inc.
Ascendis Pharma A/S
Biogenomics Limited
Bolder Biotechnology, Inc.
Braasch Biotech LLC
Carlina Technologies SAS
Critical Pharmaceuticals Limited
Delpor, Inc.
Flamel Technologies S.A.
Genexine, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Inbiopro Solutions Pvt. Ltd.
JCR Pharmaceuticals Co., Ltd.
LG Life Sciences Limited
OPKO Health, Inc.
Pfenex Inc.
Prometheon Pharma, LLC
Teva Pharmaceutical Industries Limited
Versartis, Inc.
XL-protein GmbH

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S